Cannabis-Based Products for Inflammatory Skin Diseases Show Promise but Need Trials
Topical cannabinoid products show promising early results for atopic dermatitis, psoriasis, and contact dermatitis, but controlled human clinical trials are needed to confirm efficacy and safety.
Quick Facts
What This Study Found
The discovery of a skin endocannabinoid system and its role in maintaining skin homeostasis supports the anti-inflammatory potential of topical cannabinoids. Early studies show topical cannabinoid products are generally well tolerated and have shown promising results for atopic dermatitis, psoriasis, and contact dermatitis.
Key Numbers
Over 500 biologically active compounds in cannabis; promising results in atopic dermatitis, psoriasis, and contact dermatitis; skin endocannabinoid system regulates homeostasis
How They Did This
Review of literature on the skin endocannabinoid system, cannabinoid pharmacology, and existing evidence for topical cannabinoid formulations in inflammatory skin diseases.
Why This Research Matters
Oral treatments for skin inflammation require high doses with significant side effects. Topical cannabinoid products could offer targeted treatment with fewer systemic effects, but the evidence base needs strengthening.
The Bigger Picture
As cannabis legalization expands, the market for topical cannabinoid skincare products is growing rapidly. This review separates the science from the marketing, identifying where evidence exists and where it does not.
What This Study Doesn't Tell Us
Most evidence comes from preclinical studies or small uncontrolled trials. No large randomized controlled trials of topical cannabinoids for skin disease.
Questions This Raises
- ?Which specific cannabinoids (THC, CBD, CBG) are most effective for which skin conditions?
- ?What concentrations and formulations optimize skin penetration and efficacy?
Trust & Context
- Key Stat:
- Promising results for atopic dermatitis, psoriasis, contact dermatitis
- Evidence Grade:
- Comprehensive review with strong biological rationale, but clinical evidence remains limited to small, uncontrolled studies.
- Study Age:
- Published in 2022
- Original Title:
- Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.
- Published In:
- Pharmaceuticals (Basel, Switzerland), 15(2) (2022)
- Database ID:
- RTHC-04046
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Do topical cannabis products help with eczema or psoriasis?
Early studies show promise and the science of skin cannabinoid receptors supports the concept, but large controlled trials are still needed. Products are generally well tolerated based on available data.
Why might topical cannabinoids work for skin inflammation?
The skin has its own endocannabinoid system that regulates inflammation and cell growth. Topical cannabinoids can interact with these receptors directly, potentially modulating inflammation without systemic side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04046APA
Martins, Ana M; Gomes, Ana L; Vilas Boas, Inês; Marto, Joana; Ribeiro, Helena M. (2022). Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.. Pharmaceuticals (Basel, Switzerland), 15(2). https://doi.org/10.3390/ph15020210
MLA
Martins, Ana M, et al. "Cannabis-Based Products for the Treatment of Skin Inflammatory Diseases: A Timely Review.." Pharmaceuticals (Basel, 2022. https://doi.org/10.3390/ph15020210
RethinkTHC
RethinkTHC Research Database. "Cannabis-Based Products for the Treatment of Skin Inflammato..." RTHC-04046. Retrieved from https://rethinkthc.com/research/martins-2022-cannabisbased-products-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.